PFEHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Pfizer Inc. hold a median 12-month price target of $29 — -3.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 27 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Pfizer Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Growth (40): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PFE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −3.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | JP Morgan | Maintains | Neutral | $28 → $30 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $27 → $28 |
| 6 Oct 2026 | Scotiabank | Maintains | Sector Outperform | $30 → $33 |
| 10 Sept 2026 | HSBC | Maintains | Hold | $28 → $30 |
| 10 Sept 2026 | HSBC | Maintains | Hold | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $35 → $31 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 13 July 2026 | BMO Capital | Maintains | Outperform | $34 → $30 |
| 13 July 2026 | BMO Capital | Maintains | Outperform | — |
| 13 July 2026 | Guggenheim | Maintains | Buy | — |
| 13 July 2026 | Guggenheim | Maintains | Buy | $36 → $35 |
| 10 July 2026 | B of A Securities | Maintains | Neutral | $27 → $26 |
| 10 July 2026 | B of A Securities | Maintains | Neutral | — |
| 8 July 2026 | JP Morgan | Maintains | Neutral | $30 → $28 |
| 8 July 2026 | JP Morgan | Maintains | Neutral | — |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | $27 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 6 July 2026 | HSBC | Downgrade | Hold | — |
| 6 July 2026 | HSBC | Downgrade | Hold | $32 → $28 |
| 10 June 2026 | RBC Capital | Upgrade | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PFE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Pfizer Inc. returned +28.5% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 43% of US stocks
Cheaper than 43% of US stocks
Cheaper than 42% of US stocks
Higher than 34% of US stocks
Higher than 39% of US stocks
Higher than 85% of US stocks
Higher than 86% of US stocks
Higher than 64% of US stocks
Higher than 54% of US stocks
Higher than 80% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pfizer Inc. has a market value of $169.9B and an enterprise value of $221.9B.
Revenue in the twelve months to 30 June 2026: $63.7B. The latest quarter grew 2.6% year on year.
Net income over the same four quarters: $4.4B, a 6.9% net margin.
Diluted earnings per share, trailing twelve months: $0.76.
Free cash flow in the twelve months to 30 June 2026: $11.0B.
Pfizer Inc. spent $9.8B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 39.2×; forward P/E: 10.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 5.88%, paying out 226% of earnings.
Pfizer Inc. employs 75,000 people — $849K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pfizer Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pfizer closed at $29.45 in the latest trading session, down 1.17% from the prior day. The headline notes that the stock declined as the broader market gained.
Why it matters — PFE watchers may note the stock's daily decline and its contrast with the market's gains.
Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, while declining COVID revenues and looming patent expirations present challenges.
Why it matters — PFE watchers may weigh the company's strong sales and valuation against the revenue and patent-related challenges as earnings approach.
Pfizer reported topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) monotherapy in patients with multiple myeloma. The headline says the therapy showed extended progression-free survival.
Why it matters — The results provide an update on clinical progress for a Pfizer cancer therapy.
Zacks Investment Research says Pfizer has a combination of two key ingredients that could support an earnings beat in its upcoming report. The item highlights key expectations ahead of the report.
Why it matters — PFE watchers may find the article relevant as it discusses expectations for the company’s upcoming earnings report.
Pfizer reported that its Phase 3 MagnetisMM-32 study of ELREXFIO monotherapy in adults with relapsed or refractory multiple myeloma met its primary endpoint of progression-free survival at a pre-specified interim efficacy analysis.
Why it matters — The study result is relevant to PFE watchers because it reports a positive clinical-trial outcome for ELREXFIO in the patient group described.
The 28 Wall Street analysts covering Pfizer Inc. have a median 12-month price target of $29, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Pfizer Inc., 9 rate it a Buy, 17 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Pfizer Inc. 81 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Pfizer Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies -3.2% from the last close, and Ticker Nerd's factor model ranks Pfizer Inc. 81 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pfizer Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.
Pfizer Inc. returned +28.5% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide.
The most recent item we track (Zacks Investment Research, 28 Oct 2026): "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why". Pfizer closed at $29.45 in the latest trading session, down 1.17% from the prior day. The headline notes that the stock declined as the broader market gained.
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets. The company plays a central role in global healthcare by supplying prescription therapies and immunizations across major therapeutic areas, while its research and development organization continues to support the launch, approval, and lifecycle management of new treatments. Founded in 1849 and headquartered in New York City, Pfizer Inc. remains one of the most recognized names in the pharmaceutical industry.
CEO Dr. Albert Bourla D.V.M., Ph.D. · 75,000 employees · United States · https://www.pfizer.com
